Geneticin™ selektives Antibiotikum (G418-Sulfat), Pulver
Geneticin™ selektives Antibiotikum (G418-Sulfat), Pulver
Geneticin™ selektives Antibiotikum (G418-Sulfat), Pulver
Gibco™

Geneticin™ selektives Antibiotikum (G418-Sulfat), Pulver

Geneticin™ selektives Antibiotikum (G418 Sulfat) wird erzeugt durch das Bakterium Micromonospora rhodorangea und wirkt durch Ribosombindung, wodurch die Proteinsynthese sowohlWeitere Informationen
Have Questions?
Ansicht ändernbuttonViewtableView
KatalognummerMenge
118110231 g
118110315 g
1181109825 g
Katalognummer 11811023
Preis (EUR)
178,00
Each
Menge:
1 g
Preis (EUR)
178,00
Each
Geneticin™ selektives Antibiotikum (G418 Sulfat) wird erzeugt durch das Bakterium Micromonospora rhodorangea und wirkt durch Ribosombindung, wodurch die Proteinsynthese sowohl in prokaryotischen als auch eukaryotischen Zellen gehemmt wird. Resistenz gegen Geneticin™ selektives Antibiotikum (G418 Sulfat) basiert auf Resistenzgenen von E. coli APH (3’) – I und APH (3’) – II. Gibco™ Geneticin™ selektives Antibiotikum (G418 Sulfat) dient als selektives Antibiotikum im Konzentrationsbereich von 100 bis 200 µg/ml bei Bakterien und 200 bis 500 µg/ml bei den meisten Säugetierzellen. Dieses Produkt wird als Pulver geliefert und sollte in einer Stammlösung von 10 bis 50 mg/ml in Wasser hergestellt werden. Wir bieten eine Vielzahl von Zellkultur-Antibiotika für Ihren Komfort.

Produktverwendung
Nur für Forschungszwecke: Nicht für diagnostische oder therapeutische Zwecke bei Tieren und Menschen vorgesehen.

cGMP-konformes Fertigungs- und Qualitätssystem an zwei Standorten
Zur Sicherung der Lieferkette stellen wir Gibco™ Geneticin™ Selektives Antibiotikum (G418-Sulfat) an zwei gesonderten Standorten in Grand Island, NY (USA) und Schottland (Großbritannien) her. Beide Standorte erfüllen die cGMP-Fertigungsanforderungen und sind ISO 13485-zertifiziert und bei der FDA als Hersteller medizinischer Geräte registriert.
Nur für Forschungszwecke: Nicht für diagnostische oder therapeutische Zwecke an Tieren und Menschen geeignet.
Specifications
ZelltypEukaryotische Zellen, prokaryotische Zellen
Konzentration10 bis 50 μg/ml
Zur Verwendung mit (Anwendung)Eukaryotische Auswahl⁄Erzeugung stabiler Zelllinien
ProduktlinieGeneticin
Menge1 g
Haltbarkeit24 Monate
VersandbedingungRaumtemperatur
FormPulver
ProdukttypAntibiotikum
SterilitätNon-sterile
Unit SizeEach
Inhalt und Lagerung
Lagerbedingungen: 15 bis 30 °C
Versandbedingungen: Haltbarkeit bei
Umgebungstemperatur: 24 Monate ab Herstellungsdatum

Häufig gestellte Fragen (FAQ)

Which of your antibiotics (Geneticin, Zeocin, Hygromycin B, Blasticidin, and Puromycin) can be used together for stable selection in mammalian cells?

All of our antibiotics (Geneticin, Zeocin, Hygromycin B, Blasticidin, and Puromycin) can be used together for making multiple stable cell lines. However, kill curves will need to be performed for each combination of antibiotics since sensitivity to a given antibiotic tends to increase when combined with other antibiotics.

Can Neomycin be used in mammalian selection?  Can Neomycin be used instead of Kanamycin in bacterial selection?

No, Neomycin is toxic to mammalian cells. It also causes irreversible damage to kidneys and other organs. Geneticin (aka G418 Sulfate) is a less toxic and very effective alternative for selection in mammalian cells.  Neomycin can be used in bacterial selection, but Kanamycin is the preferred drug to use because of Neomycin's toxicity.

What are the recommended concentrations of antibiotics to use for selection in prokaryotes and eukaryotes?

For best results, optimal concentrations for selection should be determined empirically in each unique experiment through dose response curves. However, to get a general idea of concentrations that have worked for individual cell types, please click on the following url: http://www.thermofisher.com/us/en/home/life-science/cell-culture/transfection/selection.html or type in “Selection Antibiotics” into our main search on www.thermofisher.com.

In contrast to Geneticin (G418)-induced cell death, cells treated with Zeocin do not always detach and float when they die. Is this typical?

It is true that a percentage of non-resistant mammalian cells do not round-up from the plate upon Zeocin selection as would be seen with G418 or Hygromycin selection. However, one should see some very characteristic morphological changes occurring in those cells that are not resistant. These cells that stick to the culture dish typically display a vast increase in size. This could be best described as being similar to the effects of cytomegalovirus infecting permissive cells. The shape of these cells may also change; taking on an "alien" shape. On close examination of the non-resistant cells, the researcher should observe a distinct breakdown of both the nuclear and plasma membranes. Even though the "cells" are still attached to the plate, they should have the appearance of many holes in these membranes. Also, before the breakdown of the membranes, one can observe open areas in the cytoplasm of the cells that appear to be large, empty vesicles. Although not confirmed, this may be explained by a breakdown of the endoplasmic reticulum and Golgi apparatus, or other scaffolding proteins. Eventually, these "cells" will completely breakdown so that only "strings" of protein are left.

In contrast, Zeocin resistant cells should continue to divide at a regular interval to form distinct clumps of cells, or colonies. There should not be a distinct change in morphology, which can be compared to cells not under selection with Zeocin. It is these colonies of actively dividing cells that contain the resistance gene and are expressing it actively.

If there is concern about the dead cells sticking to the plate, one may do the following to eliminate them: Treat the plate for a couple of minutes with trypsin/versene. Both the healthy resistant cells and the dead cells will dislodge from the plate. The cells can then be replated (without Zeocin selection) and the healthy cells will attach again while the dead ones will not. After a couple of hours when the healthy cells have attached to the substrate again, Zeocin can be added back to the medium.

What is the mode of action on the following antibiotics: Blasticidin, Geneticin (G418), Hygromycin, and Zeocin?

Blasticidin: Nucleoside Inhibits protein synthesis in prokaryotic and eukaryotic cells by interfering with peptidyl transfer reaction of protein synthesis, causing early termination of translation.

Geneticin (G418): Aminoglycoside Blocks protein synthesis in mammalian cells by interfering with ribosomal function.

Hygromycin: Aminocyclitol Inhibits protein synthesis by disrupting translocation and promoting mistranslation.

Zeocin: Intercalates with DNA and cleaves it.

Zitierungen und Referenzen (147)

Zitierungen und Referenzen
Abstract
Cloning and functional expression of a thyrotropin receptor cDNA from rat fat cells.
Authors:Endo T; Ohta K; Haraguchi K; Onaya T;
Journal:J Biol Chem
PubMed ID:7738021
Thyrotropin receptor (TSH-R) has been thought to be thyroid-specific, but, by Northern blot analysis, we found that rat adipose tissue expressed TSH-R mRNAs in amounts approaching those in the thyroid. To investigate the function of TSH-R from adipose tissue, we screened a rat fat cell lambda gt11 cDNA library for ... More
The connecting segment between both epidermal growth factor-like domains in blood coagulation factor IX contributes to stimulation by factor VIIIa and its isolated A2 domain.
Authors:Celie Patrick H N; Van Stempvoort Gunny; Fribourg Caroline; Schurgers Leon J; Lenting Peter J; Mertens Koen;
Journal:J Biol Chem
PubMed ID:11925427
The light chain of activated factor IX comprises multiple interactions between both epidermal growth factor-like domains that contribute to enzymatic activity and binding of factor IXa to its cofactor factor VIIIa. To investigate the association between factor IXa-specific properties and surface-exposed structure elements, chimeras were constructed in which the interconnection ... More
DBC2, a candidate for a tumor suppressor gene involved in breast cancer.
Authors:Hamaguchi Masaaki; Meth Jennifer L; von Klitzing Christine; Wei Wen; Esposito Diane; Rodgers Linda; Walsh Tom; Welcsh Piri; King Mary-Claire; Wigler Michael H;
Journal:Proc Natl Acad Sci U S A
PubMed ID:12370419
A previously uncharacterized gene, DBC2 (deleted in breast cancer), was cloned from a homozygously deleted region at human chromosome 8p21. DBC2 contains a highly conserved RAS domain and two putative protein interacting domains. Our analyses indicate that DBC2 is the best candidate tumor suppressor gene from this region. It lies ... More
Role of tyrosine kinase Jak2 in prolactin-induced differentiation and growth of mammary epithelial cells.
Authors:Xie Jianwu; LeBaron Matthew J; Nevalainen Marja T; Rui Hallgeir;
Journal:J Biol Chem
PubMed ID:11821424
Genetic studies in mice have established a critical role for prolactin receptors and transcription factor Stat5 in mammary gland differentiation. However, the enzymatic coupling between prolactin receptors and Stat5 in this process has not been established. In addition to Jak2, several other tyrosine kinases reportedly also are associated with prolactin ... More
A functional role for the B56 alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function.
Authors: Ruvolo Peter P; Clark Warren; Mumby Marc; Gao Fengqin; May W Stratford;
Journal:J Biol Chem
PubMed ID:11929874
'Recently it has been shown that the potent apoptotic agent ceramide activates a mitochondrial protein phosphatase 2A (PP2A) and promotes dephosphorylation of the anti-apoptotic molecule Bcl2 (Ruvolo, P. P., Deng, X., Ito, T., Carr, B. K., and May, W. S. (1999) J. Biol. Chem. 274, 20296-20300). In cells expressing Bcl2, ... More